Search Results - therapeutics

338 Results

Sort By:

Polycomb Repressive Complex 1 (PRC1) Inhibitors to Restore Immune Response in B-Cell Lymphomas

SHORT DESCRIPTION A therapeutic approach that restores MHC-II expression using PRC1 inhibitors to reactivate anti-tumor immunity in B-cell lymphomas. INVENTORS Lu Wang* Zibo Zhao * Principal Investigator NU Tech ID: NU 2025-010 IP STATUS U.S. Provisional Patent Application has been filed. THERAPEUTICS...

Published: 6/25/2026 | Updated: 6/23/2026 | Inventor(s):

Keywords(s): Cancer/Oncology, Immunotherapy, Therapeutics

Category(s): Life Sciences > Therapeutics

Compositions and Methods for Enhanced Mitochondrial Delivery for Regenerative Therapies

SHORT DESCRIPTION A novel peptide coating process that improves mitochondrial cell uptake, preserves function, and enables targeted delivery for cardiovascular and regenerative therapies. NU Tech ID NU 2025-055 INVENTORS Bin Jiang* Northwestern University Feinberg School of Medicine, Department of Surgery (Vascular...

Published: 6/18/2026 | Updated: 6/18/2026 | Inventor(s):

Keywords(s): BIO2026, Cardiology and Cardiovascular disease, MI - Myocardial Infarction, Neurodegenerative disease, Regenerative medicine, Targeted therapy, Therapeutics, Vascular disease, Vascular repair

Category(s): Life Sciences > Therapeutics

FTY720 for Treatment of Marfan Syndrome

NU2025-219 INVENTORS Tsutomu Kume* Can Tan SHORT DESCRIPTION This invention provides a novel use for FTY720, also known as Fingolimod, for the treatment and prevention of myxomatous degeneration of the mitral valve (MDMV) in Marfan syndrome. BACKGROUND Marfan syndrome, a genetic connective tissue disorder, frequently leads to MDMV, a severe...

Published: 6/18/2026 | Updated: 6/18/2026 | Inventor(s):

Keywords(s): Cardiology and Cardiovascular disease, Repurposed Drugs, Therapeutics

Category(s): Life Sciences > Therapeutics

Inhibitors of TRIP8b for Novel Mood Disorder Therapeutics

SHORT DESCRIPTION Novel inhibitors that disrupt TRIP8b-HCN binding to offer an alternative antidepressant mechanism for treatment of mood disorders. INVENTORS Gary Schiltz* Weinberg College of Arts and Sciences, Department of Chemistry Dane Chetkovich Ye Han Iredia Iyamu Kyle Lyman *...

Published: 6/17/2026 | Updated: 6/17/2026 | Inventor(s):

Keywords(s): Antidepressant, BIO2026, Depression, Mood disorder, Neurologic disease, Neurology, Psychiatric disorder, Targeted therapy, Therapeutics

Category(s): Life Sciences > Therapeutics

Bioactive Supramolecular Peptide Amphiphile Platforms for CNS In Vitro Models, CNS Regeneration, and Neurotherapeutic Delivery

SHORT DESCRIPTION A suite of self‑assembling peptide amphiphile nanostructures and hydrogels that mimic key neurotrophic factors, modulate ionic and electrical microenvironments, and protect therapeutic peptides to enhance neural survival, maturation, and regeneration across CNS diseases and injuries INVENTORS Samuel I Stupp Weinberg...

Published: 6/16/2026 | Updated: 6/16/2026 | Inventor(s):

Keywords(s): AD - Alzheimer’s Disease, ALS - Amyotrophic Lateral Sclerosis, BIO2026, Biomaterials, CNS - Central Nervous System, Drug delivery, Drug discovery, Drug screening, Hydrogel, In vitro models, Neurology, PD - Parkinson's Disease, Regenerative medicine, Research tool, Scaffold, SCI - Spinal cord injury, Smart/Functional materials, Therapeutics

Category(s): Life Sciences > Healthcare Devices, Tools & IT > Neurology, Life Sciences > Therapeutics

Protein Degraders of NSD2 for Targeted Treatment of Head and Neck Cancers

SHORT DESCRIPTION Targeted protein degraders that selectively eliminate NSD2 for improved treatment of head and neck cancers. INVENTORS Gary Schiltz* Weinberg College of Arts and Sciences, Department of Chemistry Yanis Boumber * Principal Investigator NU Tech ID: NU 2023-140 IP STATUS U.S....

Published: 6/16/2026 | Updated: 6/16/2026 | Inventor(s):

Keywords(s): BIO2026, Cancer/Oncology, Head and neck cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics

Category(s): Life Sciences > Therapeutics

Neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and neurodegenerative disorders

NU 2016-137B INVENTORS Richard Silverman Weinberg College of Arts and Sciences, Department of Chemistry SHORT DESCRIPTION Novel highly selective neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and other cancers with high expression of nNOS (e.g., gliomas, ovarian cancer) as well as neurodegenerative...

Published: 6/17/2026 | Updated: 6/16/2026 | Inventor(s):

Keywords(s): AD - Alzheimer’s Disease, ALS - Amyotrophic Lateral Sclerosis, AUTM26C1, BIAUTM1, BIO2026, Cancer/Oncology, HD - Huntington's Disease, Melanoma, Neurodegenerative disease, Neuroinflammation, Neurologic disease, nNOS, PD - Parkinson's Disease, Small molecule, Targeted therapy, Therapeutics

Category(s): Life Sciences > Therapeutics

Peptide Linkers for Modulating Antigen Immune Response in Cancer Vaccines

SHORT DESCRIPTION A novel non-biologically derived peptide linker technology enabling precise intracellular release of vaccine antigens to enhance immune activation. NU TECH ID NU 2024-124 INVENTORS Chad Mirkin* Weinberg College of Arts and Sciences, Department of Chemistry Tanner Fink *...

Published: 6/16/2026 | Updated: 6/16/2026 | Inventor(s):

Keywords(s): BIO2026, Cancer/Oncology, Immunology, Immunotherapy, Infectious disease, Therapeutics, Vaccine

Category(s): Life Sciences > Therapeutics

Biomimetic HDL Nanoparticles for Treatment of Cancer, Immune and Inflammatory Disorders, and Cardiovascular Disease

SHORT DESCRIPTION Self-assembling biomimetic high-density lipoprotein nanoparticle (HDL NP) platform technology with a soft organic core, designed to more closely replicate key functional properties of mature human HDL for therapeutic use in cardiovascular disease, cancer, and inflammatory/immune disorders. INVENTORS Colby Thaxton* Northwestern...

Published: 6/16/2026 | Updated: 6/16/2026 | Inventor(s):

Keywords(s): Atherosclerosis, Autoimmune disease, BIO2026, Breast cancer, Cancer/Oncology, Cardiology and Cardiovascular disease, Gene therapy, Immunology, Immunotherapy, Inflammation, Nanomaterials, Nanoparticle, Nanotechnology, Nucleic Acids, Platform technology, Prostate cancer, Research tool, Small molecule, Targeted therapy, Therapeutics

Category(s): Life Sciences > Biomarkers & Biomedical Research Tools, Life Sciences > Healthcare Devices, Tools & IT, Life Sciences > Therapeutics

MTHFD2-Targeting Peptide Decoy for Chemotherapy-Resistant Cancers

Application An engineered decoy peptide, DMp39, targeting DLAT-MTHFD2 interaction, as a sensitizer for chemotherapy resistant cancer treatment. Key Benefits Restores chemotherapy sensitivity in resistant tumors. Targets the DLAT-MTHFD2 pathway with high specificity and minimal off-target toxicity. Market Summary Chemotherapy resistance remains...

Published: 6/22/2026 | Updated: 6/15/2026 | Inventor(s): Sumin Kang, Jung Seok Hwang, Jaehyun Kim

Keywords(s): Oncology Treatments, Protein and Peptide Therapeutics, Therapeutics

Category(s): TechPub Algolia > Therapeutics

1 2 3 4 5 6 7 8 9 10 ...